NeuroLogic, Inc. (NLI) is a drug discovery company focused on practical and innovative solutions for Central Nervous System (CNS) disorders and diseases affecting attention, learning, and memory as well as memory disorders such as Alzheimer's disease (AD). Although the Company is clearly focused on discovery and development of therapeutics for learning and memory disorders, the Company expects to generate royalties from the first FDA approved diagnostic test for AD. NLI is completing a multi-centered, double-blind clinical trial (4Q01) with 600+ patients with Johns Hopkins University, and expects approval in the first quarter 02. This test will distinguish AD from non-AD dementias. The market (U.S.) for an FDA approved test is estimated to be 1.5MM tests/year. NLI expects to license the test to a large diagnostic/pharmaceutical company by 2002. The Company's platform science emerges from more than 30 years of research of Dr. Daniel Alkon, Chief Scientific Advisor to NLI and Scientific Director of the Blanchette Rockefeller Neurosciences Institute (BRNI). Dr. Alkon holds the Rockefeller Chair of Neuroscience. Previously, Dr. Alkon was Chief of the Laboratories of Adaptive Systems at the National Institutes of Health (NINDS), and over his career, he has published more than 300 papers in peer reviewed journals, authored books on learning and memory and holds several patents in the field of learning and memory. The insights Dr. Alkon developed over his career are now mature for product development for patients suffering from learning and memory disorders. In addition to the team he brought with him from the NIH and others recently recruited, Dr. Alkon is developing a global network of leading scientists to pursue the translation of cutting edge science into much needed drugs to improve cognition and memory. In addition to the extensive network of North American scientists, Dr. Alkon is assisting NLI in creating a global scientific advisory board with epicenters in North America, and Basel, Switzerland to capture the best ideas for drugs that enhance memory, and diminish suffering from neurological disorders affecting cognition. Prof. Gottfried Schatz (Biozentrum/Swiss Science and Technology Council) will chair the European Scientific Advisory Board (SAB) and provide guidance to NLI. Dr. Jeff Leighton (V.P. - Glaxo Pharmaceuticals, Founder/CEO of Genesis (acquired by Lilly), ICAgen, Inspire Pharmaceutical) is CEO of NLI and will establish a residence in Basel and manage the worldwide operation of the Company. The NLI proprietary drug discovery process is based on recent breakthrough insights into critical, specific, and rate limiting molecular targets discovered through a unique correlation of biochemical, biophysical, and behavioral efficacy. As a discovery company, these compounds will be developed through early proof of principle in humans (i.e., minimally through Phase I). This process combines applied clinical neuroscience with comprehensive multi-disciplinary basic neuroscience provided to NeuroLogic, in part, through it's license for intellectual property with the Blanchette Rockefeller Neurosciences Institute (BRNI), named after the late wife of John D. Rockefeller the III, who died from AD. Recent breakthroughs in the understanding of molecular and chemical events associated with attention, learning and memory have yielded numerous new validated biological targets for NLI that position the Company as first mover in the discovery of new (CNS) drug candidates that improve, or ameliorate disorders effecting learning and memory. The time for effective CNS pharmaceuticals is now, and NLI is poised to develop the first meaningful solutions for a variety of neurological conditions, and will control this space through its superior understanding of the mechanisms of learning and memory. NLI's approach emerges from detailed and comprehensive molecular "maps" that underlie basic mechanisms of learning and memory. These unique insights offer the Company proprietary opportunities to translate these new findings into novel drug targets. While NLI is learning new information about brain functions, we have identified a limited number of molecular "switches" that regulate these processes. This affords us a unique opportunity to address these "switches" to improve or enhance learning. Such molecular switches are providing targets for enhancing learning in animal models and by demonstrating efficient proof of principle, significantly reduce discovery risk. The Company further reduces risk using animal systems by demonstrating: Clear correlations of learning and memory systems in animals; Direct causal relationships established using anti-sense in living animals; Chemical leads based on predictive pharmacology and molecular events in living animals; Clinical diagnostic capability in humans. Now is the time to exploit and capture the leadership position in a market where innovative concepts in drugs have been inadequate to meet the demands of a large and growing market relating to disorders affecting learning and memory. This summary provides investors an understanding of how NLI integrates scientific leaders from around the world to work collaboratively toward the efficient discovery (and strategic value-added development) of new proprietary drugs as well as new applications for existing drugs (already approved for use in humans) that target CNS disorders affecting attention, learning and memory. Further, this summary provides a description of relevant markets, products and services; pipeline opportunities, management and global reach used for the efficient discovery of new CNS drugs.
http://www.keytechsolutions.com
Key Tech specializes contract assembly sourcing, and in providing products and services designed to improve the efficiency and profitability of manufacturers of electronics equipment. With over fifteen years experience in the design and implementation of production lines and processes, we know what it takes to successfully compete in the electronics manufacturing industry.
Synthon offers its technology to the pharmaceutical marketplace through a number of products and services, including: Chiral building blocks for drug discovery, development and manufacturing Custom synthesis of advanced intermediates based on proprietary technology Sale and/or licensing of Gateway Compounds or synthetic routes Sale and/or licensing of NDCs or key pharmacophore libraries Synthon's state-of-the-art research and development facilities and the company's worldwide manufacturing alliances insure a seamless transition for getting product from our laboratory and kilo lab into our customer's hands.
Over the past 14 years, ID Labs has provided innovative products and custom molecular biology and immunologic research services for cutting-edge Laboratory Medicine to an increasing number of customers around the world (See sample customer listing on the web at "Judge us by the company we keep"). ID Labs continues its commitment to provide quick international technical sales support and expertise to end users through its several offices and its growing network of global distributors. To best serve our American and Canadian customers, the Head Office remains in North America, and has expanded to include a new space at the recently created Biotechnology Commercialization Center at the University Research Park in London, Ontario. ID Labs still maintains its office near Sydney, Australia for the convenience of its growing number of clients in the Pacific Rim. We proudly continue to maintain an office in the UK for the convenience of our European customers. ID Labs' first commitment is to you, the life science, medical, drug-discovery and biotechnology investigator. With our growing team of highly qualified professional staff, associates, manufacturers and distributors, ID Labs invites you to join our growing number of international customers. We would like have the opportunity to contribute to your continued success and growth into 2004 and beyond. Feel free to email us at idinfo@idlabs.com with any queries or orders that you may have.
Immune Network Ltd. is a biotechnology company focused on the development of new drugs to treat major diseases predominantly involving the body's immune system. The Company's projects include Alzheimer Project AD2 and AIDS Project 1F7 and hNM01, including Hepatitis C Monoclonal Antibodies. During the year ended December 31, 2001, Immune Network suspended various projects due, in part, to fiscal constraints and for commercial reasons, although it has retained an interest in some of the projects by way of royalties in future revenues, if any. Suspended projects include Asthma Project BP1, Eczema Project BP1249, Cancer Project Viraplex, and Herpes Cold Sore Project Zorex. (Source: 20-F)
AsymmetRx, Inc. was founded in 2001 by scientists from Harvard University and Johns Hopkins University to develop novel diagnostics, imaging agents, and therapies for urologic cancers including those affecting the bladder and prostate. Using strategies based on key advisors from private and academic clinicians and pathologists specializing in urologic cancers, AsymmetRx is committed to developing the most accurate tests for the analysis of prostate and bladder biopsies, as well as early detection tests that in the future will obviate the need for needle biopsies. AsymmetRx is committed to developing systems of imaging urologic cancers that will aid in the early treatment of such diseases, as well as therapies based on specific targeting of malignant cells in urologic cancers. AsymmetRx recently succeeded in developing the first FDA cleared test for prostate cancer in needle biopsies based on the p63 antibody. It is anticipated that the p63-based test will assist in the accurate diagnosis and treatment of hundreds of thousands of men in the United States alone.
Proteos is a flexible resource for our customers. We can follow your protocols and use your cell lines, cDNAs, purification methods, etc. for carrying out a contract, and thus provide a Service leading to a product that is at a specified state of purity. Often our clients require input from Proteos in the way of a Research effort to solve one or more problems along the production train. For example, if scale-up expression and production is required but the customer has had problems with a bacterial expression system due to inclusion body formation, they may well avoid the prospect of trying to refold the protein to an active form. Proteos has special skills in protein refolding, and may explore application of our proprietary folding method, which is both elegant and cost-effective. We may also change the cDNA to optimize needed levels of expression. Protein crystallographers in large pharma, biotech companies, and academic institutions look to Proteos to provide the especially high purity proteins required for crystallography. Our track record of producing crystallographic grade protein is well documented (Proteos Bibliography) and Proteos has provided highly purified protein to customers throughout the world. Proteos also has a strategic alliance with Active Site, a protein crystallographic company in San Diego, so customers requiring both expression and purification, and x-ray structural analysis can contract all of this work in one shop.
MSM Protein Technologies is an emerging biotechnology company with proprietary technologies for generating, selecting, and optimizing human antibodies that precisely and comprehensively target multi-spanning membrane proteins ("multi-spanners"). Multi-spanners play a crucial role in cellular functions and in a large number of important human diseases: Some are targets for a number of small molecule drugs on the market today, while others have proven to be difficult for current drug discovery methods. The company believes that its proprietary drug discovery methodology will make it possible to identify and select antibodies for hundreds different multi-spanners. Antibody drugs that bind to these targets more precisely and comprehensively would offer significant benefits over existing therapies including many blockbuster small molecules drugs now in use. To date, however, handling multi-spanners for selection of such targeting compounds has been problematic. The Company's earlier proprietary methodology was reduced to practice and documented by the founder and colleagues at the Dana-Farber Cancer Institute, a Harvard University teaching affiliate. The Company has developed a sophisticated methodology and a suite of proprietary tools for handling purified multi-spanners in their native state. This advancement opens a substantial opportunity to generate new classes of antibody-based drugs to treat conditions including cancers, cardiovascular, auto-immune, inflammatory, neurodegenerative, and infectious diseases, and pain management, etc., that currently represent major unmet medical needs. Furthermore, MSM scientists have developed a novel proprietary platform technology - the Lesik/Golik platform. The platform is superior to the earlier methodology and offers much higher likelihood of the discovery of functional antibodies - those that can affect a function of a multi-spanner. The Company's fully integrated approach allows for rapid and reliable generation of antibodies targeting multi-spanners for a suite of disease targets previously deemed unreachable by conventional drug discovery methods. To date, antibodies against eleven targets have been generated. Among our competitive advantages are: reduced costs; substantially greater likelihood of success in antibody generation; much faster selection of the antibodies; shorter lead times to drug candidates (including small molecules) and to other products for biomedical research and clinical diagnostics; and broad applicability for targets that are unreachable to others and in many fields including stem cells and proteomics. The Company believes its expertise in multi-spanners makes it unique among other antibody engineering companies.
BioBlocks, Inc. was founded in San Diego in 2002 to provide custom synthesis services and sales of specialty building blocks to the drug discovery community. Over the past five years, the company has been transformed into a leading provider of medicinal chemistry and custom synthesis services. BioBlocks' building blocks business has also flourished and now features 1158 carefully selected items. BioBlocks offers its customers cost-effective chemistry outsourcing services based on its experienced management team and skilled chemistry teams in Hungary and San Diego. BioBlocks is able to offer highly competitive rates to its customers by performing most of its chemistry services in Hungary, under the close guidence of senior management. Customer service and project management are exclusively handled by the San Diego headquarters team, in order to provide excellent service to our partners. BioBlocks is proud of its fruitful relationships with both Hungarian and University of California academicians. New, patentable and/or exclusive products and technologies are being generated which will enhance the level of service BioBlocks is promising to the chemistry community.
ALSP Inc. (American Life Science Pharmaceuticals, Inc.), is a privately held company based in San Diego, California, initially focused on developing new small molecule drugs for treating Alzheimer's disease. Our approach is to identify key enzymes in the brain, called neuroproteases, which produce biologically active peptides that are thought to cause the disease. We then use those enzymes as targets for screening compounds that inhibit the neuroproteases and thereby reduce production of the harmful peptides to treat the disease. By using this innovative process, our goal is to create and advance highly-effective drug development strategies and products for Alzheimer's disease - as well as improve the quality of life for those patients who can benefit from them.
Znomics, Inc. is engaged in the business of utilizing both its technology platform and the expertise of researchers to provide new approaches to drug development for the pharmaceutical industry and for general medical research. The Company have leveraged the zebrafish in the development of its primary technology, the ZeneMark Library, a repository of retrievable zebrafish lines with identified gene mutations. Its ZeneMark Library is a searchable catalogue of mutated zebrafish lines. (Source: 10KSB)
http://www.appliedinsilico.com
Applied InSilico provides uncompromised insight into complex disease data. Our technology reveals verifiable relationships in the most complex of datasets, and dramatically reduces time and resources by allowing scientists to run pilot experiments more quickly and cost effectively. Our platform can be applied to a specific area of preclinical drug discovery or used to provide a holistic approach across the complete drug discovery pipeline.
Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Our core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of our company is on the development of unique chemical entities that operate by new cellular mechanisms. Our understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. We intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. Joyant was incorporated in November 2004 with the financial backing of Sanderling Ventures. Licensing of an intellectual property base from the University of Texas Southwestern Medical Center at Dallas was completed in February 2005.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory